Palvella Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDPalvella Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings growth of 67% provides fundamental context to the price action. However, price is extended 24% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $115.29 | +28.56% | ABOVE |
| 50 SMA | $119.32 | +24.21% | ABOVE |
| 100 SMA | $116.40 | +27.33% | ABOVE |
| 150 SMA | $109.48 | +35.38% | ABOVE |
| 200 SMA | $99.57 | +48.84% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PVLA in an uptrend right now?
PVLA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, PVLA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is PVLA overbought or oversold?
PVLA's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.
Is PVLA outperforming the market?
PVLA has a Relative Strength (RS) Rating of 91 out of 99. Yes, PVLA is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is PVLA in its 52-week range?
PVLA is trading at $148.21, which is 98% of its 52-week high ($151.18) and 98% above its 52-week low ($21.55).
How volatile is PVLA?
PVLA has a Beta of 1.74 and 52-week volatility of 81%. It's more volatile than the S&P 500 - expect bigger swings.